NCT07213167 Clinical Evaluation of Low Contrast Visual Performance and Low Light Phenomena in Patients With Various Intraocular Lens Implants
| NCT ID | NCT07213167 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dr. Daniel H. Chang, MD |
| Condition | Dysphotopsia |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-09-24 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2025-09-24 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical investigation is to evaluate visual acuity and contrast sensitivity in low lighting conditions using several different testing devices, and measure nighttime side effects of intraocular lens (IOL) implants after cataract surgery. Researchers will compare the results for three different types of IOLs to see how each lens contributes to overall visual function, patient experience and satisfaction. Participants will: * Complete two different questionnaires about their current vision * Undergo visual testing using several different devices
Eligibility Criteria
Inclusion Criteria: * Minimum 22 years of age * Bilateral pseudophakia, at least 3 months postoperative from IOL implantation, with one of the study IOL models in at least one eye. * Availability, willingness, and sufficient cognitive awareness to comply with examination procedures * Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries * Ability to understand and respond to a questionnaire in English Exclusion Criteria: * Any clinically significant pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils. * Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.) * Uncorrected distance visual acuity worse than 20/25 in either eye * Prior corneal refractive surgery (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery. Note: Prophylactic peripheral iridotomies and peripheral laser retinal repairs that, in the opinion of the investigator will not confound study outcomes are acceptable. * Posterior capsular opacification with grading worse than 1+ * Ocular findings that may, in the opinion of the investigator, affect vision and/or contrast sensitivity
Contact & Investigator
Daniel H Chang, MD
PRINCIPAL INVESTIGATOR
Empire Eye and Laser Center
Frequently Asked Questions
Who can join the NCT07213167 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, studying Dysphotopsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07213167 currently recruiting?
Yes, NCT07213167 is actively recruiting participants. Contact the research team at bcamirand@empireeyeandlaser.com for enrollment information.
Where is the NCT07213167 trial being conducted?
This trial is being conducted at Bakersfield, United States.
Who is sponsoring the NCT07213167 clinical trial?
NCT07213167 is sponsored by Dr. Daniel H. Chang, MD. The principal investigator is Daniel H Chang, MD at Empire Eye and Laser Center. The trial plans to enroll 120 participants.